Human drug discrimination: A primer and methodological review

Experimental and Clinical Psychopharmacology

Volumn 24, Issue 4, 2016, Pages 214-228

  Bolin, B Levi ^a   Alcorn, Joseph L ^a   Reynolds, Anna R ^a   Lile, Joshua A ^a,b   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Drug discrimination; Humans; Neuropharmacology; Subject rated effects; Substance use disorders

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CAFFEINE; CATHINONE; METHYLPHENIDATE; NEUROLEPTIC AGENT; NICOTINE; OPIATE; PLACEBO; PSYCHEDELIC AGENT; TOBACCO SMOKE;

ALCOHOL INTOXICATION; ARTICLE; BEHAVIOR; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; DRUG DISCRIMINATION TEST; DRUG SELF ADMINISTRATION; HUMAN; INTEROCEPTIVE STIMULUS; NEUROPHARMACOLOGY; REINFORCEMENT; SOMATOSENSORY STIMULATION; STIMULUS RESPONSE; SUBSTANCE ABUSE; SUBSTANCE USE; ANIMAL; DRUG EFFECTS; PERCEPTIVE DISCRIMINATION; PROCEDURES; PSYCHOLOGY; PSYCHOPHARMACOLOGY; SUBSTANCE-RELATED DISORDERS;

ANIMALS; DISCRIMINATION (PSYCHOLOGY); HUMANS; PSYCHOPHARMACOLOGY; SUBSTANCE-RELATED DISORDERS;

EID: 84979915606     PISSN: 10641297     EISSN: 19362293     Source Type: Journal    
DOI: 10.1037/pha0000077     Document Type: Article

References (125)

1. Alleweireldt, A. T., Weber, S. M., & Neisewander, J. L. (2001). Passive exposure to a contextual discriminative stimulus reinstates cocaineseeking behavior in rats. Pharmacology, Biochemistry, and Behavior, 69, 555-560. http://dx.doi.org/10.1016/S0091-3057(01)00573-1.
2. Banks, M. L., Czoty, P. W., & Nader, M. A. (2007). The influence of reinforcing effects of cocaine on cocaine-induced increases in extinguished responding in cynomolgus monkeys. Psychopharmacology, 192, 449-456. http://dx.doi.org/10.1007/s00213-007-0732-0.
3. Bickel, W. K., Bigelow, G. E., Preston, K. L., & Liebson, I. A. (1989). Opioid drug discrimination in humans: Stability, specificity and relation to self-reported drug effect. The Journal of Pharmacology and Experimental Therapeutics, 251, 1053-1063. Retrieved from http://www.ncbi .nlm.nih.gov/pubmed/2481029.
4. Bickel, W. K., & Kelly, T. H. (1988). The relationship of stimulus control to the treatment of substance abuse. National Institute on Drug Abuse Research Monograph Series, 84, 122-140. Retrieved from http://www .ncbi.nlm.nih.gov/pubmed/3147379.
5. Bickel, W. K., Oliveto, A. H., Kamien, J. B., Higgins, S. T., & Hughes, J. R. (1993). A novel-response procedure enhances the selectivity and sensitivity of a triazolam discrimination in humans. The Journal of Pharmacology and Experimental Therapeutics, 264, 360-367. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8423538.
6. Boctor, S. Y., Martinez, J. L., Jr., Koek, W., & France, C. P. (2007). The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. European Journal of Pharmacology, 571, 39-43. http://dx.doi.org/10.1016/j.ejphar.2007.06.004.
7. Brauer, L. H., & de Wit, H. (1996). Subjective responses to d-amphetamine alone and after pimozide pretreatment in normal, healthy volunteers. Biological Psychiatry, 39, 26-32. http://dx.doi.org/10.1016/0006-3223(95)00110-7.
8. Brauer, L. H., & De Wit, H. (1997). High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacology, Biochemistry, and Behavior, 56, 265-272. http://dx.doi.org/10.1016/ S0091-3057(96)00240-7.
9. Brauer, L. H., Goudie, A. J., & de Wit, H. (1997). Dopamine ligands and the stimulus effects of amphetamine: Animal models versus human laboratory data. Psychopharmacology, 130, 2-13. http://dx.doi.org/10 .1007/s002130050207.
10. Brauer, L. H., Rukstalis, M. R., & de Wit, H. (1995). Acute subjective responses to paroxetine in normal volunteers. Drug and Alcohol Dependence, 39, 223-230. http://dx.doi.org/10.1016/0376-8716(95)01173-2.
11. Carroll, M. E., & Comer, S. D. (1996). Animal models of relapse. Experimental and Clinical Psychopharmacology, 4, 11-18. http://dx.doi.org/ 10.1037/1064-1297.4.1.11.
12. Chait, L. D., Evans, S. M., Grant, K. A., Kamien, J. B., Johanson, C. E., & Schuster, C. R. (1988). Discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology, 94, 206-212. http://dx.doi.org/10.1007/BF00176846.
13. Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1984). An experimental paradigm for studying the discriminative stimulus properties of drugs in humans. Psychopharmacology, 82, 272-274. http://dx.doi.org/10.1007/ BF00427789.
14. Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1985). The discriminative stimulus and subjective effects of d-amphetamine in humans. Psychopharmacology, 86, 307-312. http://dx.doi.org/10.1007/ BF00432219.
15. Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1986a). The discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d-amphetamine in humans. Pharmacology, Biochemistry, and Behavior, 24, 1665-1672. http://dx.doi.org/10.1016/0091-3057(86) 90503-4.
16. Chait, L. D., Uhlenhuth, E. H., & Johanson, C. E. (1986b). The discriminative stimulus and subjective effects of d-amphetamine, phenmetrazine and fenfluramine in humans. Psychopharmacology, 89, 301-306. http://dx.doi.org/10.1007/BF00174364.
17. Colpaert, F. C. (1991). The discriminative response: An elementary particle of behavior. Commentary on Stolerman "Measures of stimulus generalization in drug discrimination experiments." Behavioural Pharmacology, 2, 283-286. Retrieved from http://www.ncbi.nlm.nih.gov/ pubmed/11224071.
18. Colpaert, F. C. (1999). Drug discrimination in neurobiology. Pharmacology, Biochemistry, and Behavior, 64, 337-345. http://dx.doi.org/10 .1016/S0091-3057(99)00047-7.
19. Colpaert, F. C., Kuyps, J. J., Niemegeers, C. J., & Janssen, P. A. (1976). Discriminative stimulus properties of a low dl-amphetamine dose. Archives Internationales de Pharmacodynamie et de Therapie, 223, 34-42. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/999400.
20. Combe, G. A. (1830). A system of phrenology (3rd ed.). Edinburgh, UK: John Anderson Publisher's.
21. Conger, J. J. (1951). The effects of alcohol on conflict behavior in the albino rat. Quarterly Journal of Studies on Alcohol, 12, 1-29. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14828044.
22. Craig, A. D. (2002). How do you feel? Interoception: The sense of the physiological condition of the body. Nature Reviews Neuroscience, 3, 655-666. http://dx.doi.org/10.1038/nrn894.
23. Czoty, P. W., Ramanathan, C. R., Mutschler, N. H., Makriyannis, A., & Bergman, J. (2004). Drug discrimination in methamphetamine-trained monkeys: Effects of monoamine transporter inhibitors. The Journal of Pharmacology and Experimental Therapeutics, 311, 720-727. http://dx .doi.org/10.1124/jpet.104.071035.
24. DeGrandpre, R. J., & Bickel, W. K. (1993). Stimulus control and drug dependence. The Psychological Record, 43, 651-666.
25. de Wit, H. (1996). Priming effects with drugs and other reinforcers. Experimental and Clinical Psychopharmacology, 4, 5-10. http://dx.doi.org/10.1037/1064-1297.4.1.5.
26. Fischman, M. W., & Foltin, R. W. (1991). Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. British Journal of Addiction, 86, 1563-1570. http://dx.doi.org/10.1111/j.1360-0443.1991.tb01749.x.
27. Foltin, R. W., & Fischman, M. W. (1988). Ethanol and cocaine interactions in humans: Cardiovascular consequences. Pharmacology, Biochemistry, and Behavior, 31, 877-883. http://dx.doi.org/10.1016/0091-3057(88)90399-1.
28. France, C. P., & Woods, J. H. (1985). Opiate agonist-antagonist interactions: Application of a three-key drug discrimination procedure. The Journal of Pharmacology and Experimental Therapeutics, 234, 81-89. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4009506.
29. Gatch, M. B., Taylor, C. M., Flores, E., Selvig, M., & Forster, M. J. (2006). Effects of monoamine oxidase inhibitors on cocaine discrimination in rats. Behavioural Pharmacology, 17, 151-159. http://dx.doi.org/10.1097/01.fbp.0000197459.08892.b5.
30. Glennon, R. A., Järbe, T. U., & Frankenheim, J. (1991). Drug discrimination: Applications to drug abuse research. National Institute on Drug Abuse Research Monograph Series, 1991, 116.
31. Grabowski, J., Shearer, J., Merrill, J., & Negus, S. S. (2004). Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors, 29, 1439-1464. http://dx.doi.org/10.1016/j.addbeh.2004.06.018.
32. Griffiths, R. R., Evans, S. M., Heishman, S. J., Preston, K. L., Sannerud, C. A., Wolf, B., & Woodson, P. P. (1990). Low-dose caffeine discrimination in humans. The Journal of Pharmacology and Experimental Therapeutics, 252, 970-978.
33. Haertzen, C. A., Hill, H. E., & Belleville, R. E. (1963). Development of the Addiction Research Center Inventory (ARCI): Selection of items that are sensitive to the effects of various drugs. Psychopharmacology, 4, 155-166. http://dx.doi.org/10.1007/BF02584088.
34. Hart, C. L., Haney, M., Foltin, R. W., & Fischman, M. W. (2002). Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology, 164, 376-384. http://dx.doi.org/10.1007/s00213-002-1225-9.
35. Herin, D. V., Rush, C. R., & Grabowski, J. (2010). Agonist-like pharmacotherapy for stimulant dependence: Preclinical, human laboratory, and clinical studies. Annals of the New York Academy of Sciences, 1187, 76-100. http://dx.doi.org/10.1111/j.1749-6632.2009.05145.x.
36. Higgins, S. T., Bickel, W. K., Hughes, J. R., Lynn, M., Capeless, M. A., & Fenwick, J. W. (1990). Effects of intranasal cocaine on human learning, performance and physiology. Psychopharmacology, 102, 451-458. http://dx.doi.org/10.1007/BF02247124.
37. Higgins, S. T., Rush, C. R., Bickel, W. K., Hughes, J. R., Lynn, M., & Capeless, M. A. (1993). Acute behavioral and cardiac effects of cocaine and alcohol combinations in humans. Psychopharmacology, 111, 285-294. http://dx.doi.org/10.1007/BF02244943.
38. Hoffman, A. C., & Evans, S. E. (2013). Abuse potential of non-nicotine tobacco smoke components: Acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine and Tobacco Research, 15, 622-632. http://dx.doi .org/10.1093/ntr/nts192.
39. Holtzman, S. G., & Locke, K. W. (1988). Neural mechanisms of drug stimuli: Experimental approaches. Psychopharmacology Series, 4, 138-153. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3293038.
40. Hölzl, R., Erasmus, L. P., & Möltner, A. (1996). Detection, discrimination and sensation of visceral stimuli. Biological Psychology, 42, 199-214. http://dx.doi.org/10.1016/0301-0511(95)05155-4.
41. Hunter-Reel, D., McCrady, B., & Hildebrandt, T. (2009). Emphasizing interpersonal factors: An extension of the Witkiewitz and Marlatt relapse model. Addiction, 104, 1281-1290. http://dx.doi.org/10.1111/j.1360-0443.2009.02611.x.
42. Huskinson, S. L., Naylor, J. E., Rowlett, J. K., & Freeman, K. B. (2014). Predicting abuse potential of stimulants and other dopaminergic drugs: Overview and recommendations. Neuropharmacology, 87, 66-80. http://dx.doi.org/10.1016/j.neuropharm.2014.03.009.
43. Iversen, L., White, M., & Treble, R. (2014). Designer psychostimulants: Pharmacology and differences. Neuropharmacology, 87, 59-65. http:// dx.doi.org/10.1016/j.neuropharm.2014.01.015.
44. Jellinek, E. M. (1946). Rôle of the placebo in tests for drug discrimination. Federation Proceedings, 5, 184. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21064408.
45. Johanson, C. E. (1991a). Discriminative stimulus effects of diazepam in humans. The Journal of Pharmacology and Experimental Therapeutics, 257, 634-643. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/ 2033509.
46. Johanson, C. E. (1991b). Discriminative stimulus effects of psychomotor stimulants and benzodiazepines in humans. National Institute on Drug Abuse Research Monograph Series, 116, 181-196. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/1369667.
47. Johanson, C. E. (1992). The use of human drug discrimination studies in medication development. National Institute on Drug Abuse Research Monograph Series, 119, 180-184. Retrieved from http://www.ncbi.nlm .nih.gov/pubmed/1435976.
48. Johanson, C. E., Kilbey, M., Gatchalian, K., & Tancer, M. (2006). Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans trained to discriminate among d-amphetamine, meta-chlorophenylpiperazine and placebo. Drug and Alcohol Dependence, 81, 27-36. http://dx.doi.org/10.1016/j.drugalcdep.2005.05.003.
49. Johanson, C. E., Lundahl, L. H., & Schubiner, H. (2007). Effects of oral cocaine on intravenous cocaine discrimination in humans. Experimental and Clinical Psychopharmacology, 15, 219-227. http://dx.doi.org/10 .1037/1064-1297.15.3.219.
50. Kamien, J. B., Bickel, W. K., Hughes, J. R., Higgins, S. T., & Smith, B. J. (1993). Drug discrimination by humans compared to nonhumans: Current status and future directions. Psychopharmacology, 111, 259-270. http://dx.doi.org/10.1007/BF02244940.
51. Katz, J. L., & Higgins, S. T. (2003). The validity of the reinstatement model of craving and relapse to drug use. Psychopharmacology, 168, 21-30. http://dx.doi.org/10.1007/s00213-003-1441-y.
52. Kelly, T. H., Emurian, C. S., Baseheart, B. J., & Martin, C. A. (1997). Discriminative stimulus effects of alcohol in humans. Drug and Alcohol Dependence, 48, 199-207. http://dx.doi.org/10.1016/S0376-8716 (97)00126-9.
53. Kelly, T. H., Stoops, W. W., Perry, A. S., Prendergast, M. A., & Rush, C. R. (2003). Clinical neuropharmacology of drugs of abuse: A comparison of drug-discrimination and subject-report measures. Behavioral and Cognitive Neuroscience Reviews, 2, 227-260. http://dx.doi.org/10 .1177/1534582303262095.
54. Kollins, S. H., & Rush, C. R. (1999). Effects of training dose on the relationship between discriminative-stimulus and self-reported drug effects of d-amphetamine in humans. Pharmacology, Biochemistry, and Behavior, 64, 319-326. http://dx.doi.org/10.1016/S0091-3057(99) 00084-2.
55. Lelas, S., Spealman, R. D., & Rowlett, J. K. (2000). Using behavior to elucidate receptor mechanisms: A review of the discriminative stimulus effects of benzodiazepines. Experimental and Clinical Psychopharmacology, 8, 294-311. http://dx.doi.org/10.1037/1064-1297.8.3.294.
56. Lile, J. A., Stoops, W. W., Durell, T. M., Glaser, P. E., & Rush, C. R. (2006). Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Experimental and Clinical Psychopharmacology, 14, 136-147. http:// dx.doi.org/10.1037/1064-1297.14.2.136.
57. Lile, J. A., Stoops, W. W., Glaser, P. E., Hays, L. R., & Rush, C. R. (2011). Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. Journal of Psychopharmacology, 25, 1469-1479. http://dx.doi.org/10.1177/ 0269881110385597.
58. Lile, J. A., Stoops, W. W., Vansickel, A. R., Glaser, P. E., Hays, L. R., & Rush, C. R. (2005). Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology, 30, 2103-2114. http://dx.doi.org/10.1038/sj.npp.1300803.
59. Lile, J. A., Stoops, W. W., Wagner, F. P., Glaser, P. E., & Rush, C. R. (2005). Oxazepam does not modulate the behavioral effects of d-amphetamine in humans. Pharmacology, Biochemistry, and Behavior, 82, 270-279. http://dx.doi.org/10.1016/j.pbb.2005.08.012.
60. Lukas, S. E., Sholar, M., Lundahl, L. H., Lamas, X., Kouri, E., Wines, J. D.,. Mendelson, J. H. (1996). Sex differences in plasma cocaine levels and subjective effects after acute cocaine administration in human volunteers. Psychopharmacology, 125, 346-354. http://dx.doi.org/10 .1007/BF02246017.
61. McFarland, K., & Ettenberg, A. (1997). Reinstatement of drug-seeking behavior produced by heroin-predictive environmental stimuli. Psychopharmacology, 131, 86-92. http://dx.doi.org/10.1007/s002130050269.
62. McKay, J. R. (1999). Studies of factors in relapse to alcohol, drug and nicotine use: A critical review of methodologies and findings. Journal of Studies on Alcohol, 60, 566-576. http://dx.doi.org/10.15288/jsa.1999.60 .566.
63. McMahon, L. R. (2015). The rise (and fall?) of drug discrimination research. Drug and Alcohol Dependence, 151, 284-288. http://dx.doi .org/10.1016/j.drugalcdep.2015.04.001.
64. Mori, T., Yoshizawa, K., Shibasaki, M., & Suzuki, T. (2012). Discriminative stimulus effects of hallucinogenic drugs: A possible relation to reinforcing and aversive effects. Journal of Pharmacological Sciences, 120, 70-76. http://dx.doi.org/10.1254/jphs.12R08CP.
65. Munzar, P., Baumann, M. H., Shoaib, M., & Goldberg, S. R. (1999). Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats. Psychopharmacology, 141, 287-296. http://dx.doi.org/10.1007/s002130050836.
66. Naqvi, N. H., & Bechara, A. (2010). The insula and drug addiction: An interoceptive view of pleasure, urges, and decision-making. Brain Structure & Function, 214, 435-450. http://dx.doi.org/10.1007/s00429-010-0268-7.
67. Nielsen, E. B., & Scheel-Krüger, J. (1988). Central nervous system stimulants: Neuropharmacological mechanisms. Psychopharmacology Series, 4, 57-72. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/ 2899318.
68. Odum, A. L., & Shahan, T. A. (2004). D-Amphetamine reinstates behavior previously maintained by food: Importance of context. Behavioural Pharmacology, 15, 513-516. http://dx.doi.org/10.1097/00008877-200411000-00007.
69. Oliveto, A. H., Bickel, W. K., Hughes, J. R., Shea, P. J., Higgins, S. T., & Fenwick, J. W. (1992). Caffeine drug discrimination in humans: Acquisition, specificity and correlation with self-reports. The Journal of Pharmacology and Experimental Therapeutics, 261, 885-894.
70. Oliveto, A. H., Bickel, W. K., Kamien, J. B., Hughes, J. R., & Higgins, S. T. (1994). Effects of diazepam and hydromorphone in triazolamtrained humans under a novel-response drug discrimination procedure. Psychopharmacology, 114, 417-423. http://dx.doi.org/10.1007/BF 02249331.
71. Oliveto, A., Mancino, M., Sanders, N., Cargile, C., Benjamin Guise, J., Bickel, W., & Brooks Gentry, W. (2013). Effects of prototypic calcium channel blockers in methadone-maintained humans responding under a naloxone discrimination procedure. European Journal of Pharmacology, 715, 424-435. http://dx.doi.org/10.1016/j.ejphar.2013.03.007.
72. Oliveto, A. H., Rosen, M. I., Woods, S. W., & Kosten, T. R. (1995). Discriminative stimulus, self-reported and cardiovascular effects of orally administered cocaine in humans. The Journal of Pharmacology and Experimental Therapeutics, 272, 231-241. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/7815337.
73. Oliveto, A., Sevarino, K., McCance-Katz, E., & Feingold, A. (2002). Butorphanol and nalbuphine in opioid-dependent humans under a naloxone discrimination procedure. Pharmacology, Biochemistry, and Behavior, 71, 85-96. http://dx.doi.org/10.1016/S0091-3057(01)00637-2.
74. Overton, D. A. (1974). Experimental methods for the study of statedependent learning. Federation Proceedings, 33, 1800-1813. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/4599463.
75. Overton, D. A. (1991). A historical perspective on drug discrimination. National Institute on Drug Abuse Research Monograph Series, 116, 5-24. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1369681.
76. Paulus, M. P., & Stewart, J. L. (2014). Interoception and drug addiction. Neuropharmacology, 76, 342-350. http://dx.doi.org/10.1016/j.neuropharm.2013.07.002.
77. Perkins, K. A., D'Amico, D., Sanders, M., Grobe, J. E., Wilson, A., & Stiller, R. L. (1996). Influence of training dose on nicotine discrimination in humans. Psychopharmacology, 126, 132-139. http://dx.doi.org/ 10.1007/BF02246348.
78. Perkins, K. A., Fonte, C., Sanders, M., White, W., & Wilson, A. (1999). Effects of training dose and two- versus three-choice testing procedure on nicotine discrimination responding in humans. Psychopharmacology, 145, 418-425. http://dx.doi.org/10.1007/s002130051076.
79. Porter, J. H., & Prus, A. J. (2009a). Drug discrimination: 30 years of progress. Psychopharmacology, 203, 189-191. http://dx.doi.org/10 .1007/s00213-009-1478-7.
80. Porter, J. H., & Prus, A. J. (2009b). Discriminative stimulus properties of atypical and typical antipsychotic drugs: A review of preclinical studies. Psychopharmacology, 203, 279-294. http://dx.doi.org/10.1007/s00213-008-1308-3.
81. Powell, K. R., & Holtzman, S. G. (2000). Modulation of the discriminative stimulus effects of d-amphetamine by mu and kappa opioids in squirrel monkeys. Pharmacology, Biochemistry, and Behavior, 65, 43-51. http:// dx.doi.org/10.1016/S0091-3057(99)00183-5.
82. Preston, K. L. (1991). Drug discrimination methods in human drug abuse liability evaluation. British Journal of Addiction, 86, 1587-1594. http:// dx.doi.org/10.1111/j.1360-0443.1991.tb01752.x.
83. Preston, K. L., & Bigelow, G. E. (1991). Subjective and discriminative effects of drugs. Behavioural Pharmacology, 2, 293-313. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11224073.
84. Preston, K. L., & Bigelow, G. E. (2000). Effects of agonist-antagonist opioids in humans trained in a hydromorphone/not hydromorphone discrimination. The Journal of Pharmacology and Experimental Therapeutics, 295, 114-124. Retrieved from http://www.ncbi.nlm.nih.gov/ pubmed/10991968.
85. Preston, K. L., Bigelow, G. E., Bickel, W., & Liebson, I. A. (1987). Three-choice drug discrimination in opioid-dependent humans: Hydromorphone, naloxone and saline. The Journal of Pharmacology and Experimental Therapeutics, 243, 1002-1009. Retrieved from http:// www.ncbi.nlm.nih.gov/pubmed/2447262.
86. Preston, K. L., Bigelow, G. E., Bickel, W. K., & Liebson, I. A. (1989). Drug discrimination in human postaddicts: Agonist-antagonist opioids. The Journal of Pharmacology and Experimental Therapeutics, 250, 184-196. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/ 2473187.
87. Preston, K. L., Bigelow, G. E., & Liebson, I. A. (1990). Discrimination of butorphanol and nalbuphine in opioid-dependent humans. Pharmacology, Biochemistry, and Behavior, 37, 511-522. http://dx.doi.org/10 .1016/0091-3057(90)90021-9.
88. Preston, K. L., Liebson, I. A., & Bigelow, G. E. (1992). Discrimination of agonist-antagonist opioids in humans trained on a two-choice salinehydromorphone discrimination. The Journal of Pharmacology and Experimental Therapeutics, 261, 62-71. Retrieved from http://www.ncbi .nlm.nih.gov/pubmed/1373189.
89. Reisine, T., & Pasternak, G. (1996). Opioid analgesics and antagonists. In J. G. Hardman, L. E. Limbird, P. B. Molinoff, R. W. Ruddon, & A. G. Gilman (Eds.), Goodman's and Filman's: The pharmacological basis of therapeutics (9th ed., pp. 521-555). New York, NY: McGraw-Hill.
90. Reynolds, A. R., Bolin, B. L., Stoops, W. W., & Rush, C. R. (2013). Relationship between drug discrimination and ratings of subjective effects: Implications for assessing and understanding the abuse potential of D-amphetamine in humans. Behavioural Pharmacology, 24, 523-532. http://dx.doi.org/10.1097/FBP.0b013e328364505f.
91. Ribot, T. (1891). The diseases of personality (4th ed.). Chicago, IL: Open Court.
92. Rush, C. R., & Baker, R. W. (2001). Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers. Experimental and Clinical Psychopharmacology, 9, 59-73. http://dx.doi.org/ 10.1037/1064-1297.9.1.59.
93. Rush, C. R., Critchfield, T. S., Troisi, J. R., & Griffiths, R. R. (1995). Discriminative stimulus effects of diazepam and buspirone in normal volunteers. Journal of the Experimental Analysis of Behavior, 63, 277-294. http://dx.doi.org/10.1901/jeab.1995.63-277.
94. Rush, C. R., Kelly, T. H., Hays, L. R., & Wooten, A. F. (2002). Discriminative-stimulus effects of modafinil in cocaine-trained humans. Drug and Alcohol Dependence, 67, 311-322. http://dx.doi.org/10.1016/ S0376-8716(02)00082-0.
95. Rush, C. R., Kollins, S. H., & Pazzaglia, P. J. (1998). Discriminativestimulus and participant-rated effects of methylphenidate, bupropion, and triazolam in d-amphetamine-trained humans. Experimental and Clinical Psychopharmacology, 6, 32-44. http://dx.doi.org/10.1037/ 1064-1297.6.1.32.
96. Rush, C. R., Stoops, W. W., Hays, L. R., Glaser, P. E., & Hays, L. S. (2003). Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. The Journal of Pharmacology and Experimental Therapeutics, 306, 195-204. http://dx.doi.org/10.1124/jpet.102.048439.
97. Rush, C. R., Stoops, W. W., Wagner, F. P., Hays, L. R., & Glaser, P. E. (2004). Alprazolam attenuates the behavioral effects of d-amphetamine in humans. Journal of Clinical Psychopharmacology, 24, 410-420. http://dx.doi.org/10.1097/01.jcp.0000130553.55630.ad.
98. Rush, C. R., Vansickel, A. R., & Stoops, W. W. (2011). Human drug discrimination: Methodological considerations and application to elucidating the neuropharmacology of amphetamines. In R. A. Glennon & R. Young (Eds.), Drug discrimination: Applications to medicinal chemistry and drug studies (pp. 431-461). Hoboken, NJ: Wiley. http://dx.doi.org/10.1002/9781118023150.ch14.
99. Schechter, M. D. (1998). "Candyflipping:" Synergistic discriminative effect of LSD and MDMA. European Journal of Pharmacology, 341, 131-134. http://dx.doi.org/10.1016/S0014-2999(97)01473-8.
100. Schuh, K. J., Schubiner, H., & Johanson, C. E. (2000). Discrimination of intranasal cocaine. Behavioural Pharmacology, 11, 511-515. http://dx.doi.org/10.1097/00008877-200009000-00008.
101. Schuster, C. R., Fischman, M. W., & Johanson, C. E. (1981). Internal stimulus control and subjective effects of drugs. National Institute on Drug Abuse Research Monograph Series, 37, 116-129. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/6798454.
102. Schuster, C. R., & Johanson, C. E. (1988). Relationship between the discriminative stimulus properties and subjective effects of drugs. Psychopharmacology Series, 4, 161-175. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/3293041.
103. Sevak, R. J., Stoops, W. W., Hays, L. R., & Rush, C. R. (2009). Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetaminetrained humans. The Journal of Pharmacology and Experimental Therapeutics, 328, 1007-1018. http://dx.doi.org/10.1124/jpet.108.147124.
104. Sevak, R. J., Vansickel, A. R., Stoops, W. W., Glaser, P. E., Hays, L. R., & Rush, C. R. (2011). Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole. Journal of Clinical Psychopharmacology, 31, 470-480. http:// dx.doi.org/10.1097/JCP.0b013e318221b2db.
105. Shaham, Y., & Miczek, K. A. (2003). Reinstatement-Toward a model of relapse. Psychopharmacology, 168, 1-2. http://dx.doi.org/10.1007/s00 213-003-1469-z.
106. Shaham, Y., Shalev, U., Lu, L., De Wit, H., & Stewart, J. (2003). The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology, 168, 3-20. http://dx.doi.org/10.1007/ s00213-002-1224-x.
107. Shalev, U., Grimm, J. W., & Shaham, Y. (2002). Neurobiology of relapse to heroin and cocaine seeking: A review. Pharmacological Reviews, 54, 1-42. http://dx.doi.org/10.1124/pr.54.1.1.
108. Silverman, K., & Griffiths, R. R. (1992). Low-dose caffeine discrimination and self-reported mood effects in normal volunteers. Journal of the Experimental Analysis of Behavior, 57, 91-107. http://dx.doi.org/10 .1901/jeab.1992.57-91.
109. Sinha, R., & Li, C. S. (2007). Imaging stress- and cue-induced drug and alcohol craving: Association with relapse and clinical implications. Drug and Alcohol Review, 26, 25-31. http://dx.doi.org/10.1080/09595230 601036960.
110. Spealman, R. D., Barrett-Larimore, R. L., Rowlett, J. K., Platt, D. M., & Khroyan, T. V. (1999). Pharmacological and environmental determinants of relapse to cocaine-seeking behavior. Pharmacology, Biochemistry, and Behavior, 64, 327-336. http://dx.doi.org/10.1016/S0091-30 57(99)00049-0.
111. Stolerman, I. P. (1991). Behavioural pharmacology of nicotine: Multiple mechanisms. British Journal of Addiction, 86, 533-536. http://dx.doi .org/10.1111/j.1360-0443.1991.tb01803.x.
112. Stoops, W. W., Lile, J. A., Glaser, P. E., & Rush, C. R. (2005). Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Experimental and Clinical Psychopharmacology, 13, 56-64. http://dx.doi .org/10.1037/1064-1297.13.1.56.
113. Stoops, W. W., Lile, J. A., Glaser, P. E., & Rush, C. R. (2006). A low dose of aripiprazole attenuates the subject-rated effects of d-amphetamine. Drug and Alcohol Dependence, 84, 206-209. http://dx.doi.org/10.1016/ j.drugalcdep.2006.02.004.
114. Stretch, R., & Gerber, G. J. (1973). Drug-induced reinstatement of amphetamine self-administration behaviour in monkeys. Canadian Journal of Psychology, 27, 168-177. http://dx.doi.org/10.1037/h0082466.
115. Strickland, J. C., Rush, C. R., & Stoops, W. W. (2015). Mu opioid mediated discriminative-stimulus effects of tramadol: An individual subjects analysis. Journal of the Experimental Analysis of Behavior, 103, 361-374. http://dx.doi.org/10.1002/jeab.137.
116. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. (2015). Results from the 2014 National survey on Drug Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from http://www.samhsa.gov/data/population-data-nsduh/reports?tab=32.
117. Terry, P., Witkin, J. M., & Katz, J. L. (1994). Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. The Journal of Pharmacology and Experimental Therapeutics, 270, 1041-1048. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7932151.
118. Tidey, J. W., & Bergman, J. (1998). Drug discrimination in methamphetamine-trained monkeys: Agonist and antagonist effects of dopaminergic drugs. The Journal of Pharmacology and Experimental Therapeutics, 285, 1163-1174. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/9618419.
119. Verdejo-Garcia, A., Clark, L., & Dunn, B. D. (2012). The role of interoception in addiction: A critical review. Neuroscience and Biobehavioral Reviews, 36, 1857-1869. http://dx.doi.org/10.1016/j.neubiorev.2012.05.007.
120. Wachtel, S. R., Ortengren, A., & de Wit, H. (2002). The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug and Alcohol Dependence, 68, 23-33. http:// dx.doi.org/10.1016/S0376-8716(02)00104-7.
121. White, J. M., & Holtzman, S. G. (1981). Three-choice drug discrimination in the rat: Morphine, cyclazocine and saline. The Journal of Pharmacology and Experimental Therapeutics, 217, 254-262. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/7229971.
122. White, J. M., & Holtzman, S. G. (1983). Three-choice drug discrimination: Phencyclidine-like stimulus effects of opioids. Psychopharmacology, 80, 1-9. http://dx.doi.org/10.1007/BF00427484.
123. Woods, J. H., Bertalmio, A. J., Young, A. M., Essman, W. D., & Winger, G. (1988). Receptor mechanisms of opioid drug discrimination. Psychopharmacology Series, 4, 95-106. Retrieved from http://www.ncbi.nlm .nih.gov/pubmed/2839823.
124. Yan, Y., Yamada, K., Niwa, M., Nagai, T., Nitta, A., & Nabeshima, T. (2007). Enduring vulnerability to reinstatement of methamphetamineseeking behavior in glial-cell-line-derived neurotrophic factor mutant mice. The Federation of American Societies of Experimental Biology (FASEB). Journal, 21, 1994-2004.
125. Young, R. (1991). Discriminative stimulus properties of benzodiazepines and several new anxiolytics. National Institute on Drug Abuse Research Monograph Series, 116, 117-130. Retrieved from http://www.ncbi.nlm .nih.gov/pubmed/1369663.